Back to results
US 12,715,911 B2Granted
Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for use in intervention and therapy of congestion in a patient in need thereof
AssigneeAdrenomed AG
InventorAdriaan Voors
Life of this patent
Estimating the term…
Abstract
Subject matter of the present invention is an anti-Adrenomedullin (ADM) antibody or an anti-Adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in intervention and therapy of congestion in a patient in need thereof.
Claims6
A method for the treatment of residual congestion in a patient with heart failure who has been treated with diuretics, wherein residual congestion is defined as the presence of congestion after the treatment with diuretics the method comprising:
- administering to a patient in the need thereof, an effective amount of Anti-adrenomedullin (ADM) antibody or an anti-ADM-antibody fragment, wherein said anti-ADM antibody or anti-ADM-antibody fragment binds to the N-terminal part (aa 1-21) of adrenomedullin:
- (SEQ ID NO:
- 22)
- YRQSMNNFQGLRSFGCRFGTC;
- wherein the anti-adrenomedullin (ADM) antibody or an anti-ADM-antibody fragment comprises a heavy chain and a light chain, wherein the heavy chain comprises the sequences:
- SEQ ID NO:
- 1
- GYTFSRYW,
- SEQ ID NO:
- 2
- ILPGSGST,
- and
- SEQ ID NO:
- 3
- TEGYEYDGFDY
- and wherein the light chain comprises the sequences:
- SEQ ID NO:
- 4
- QSIVYSNGNTY,
- SEQUENCE:
- RVS,
- and
- SEQ ID NO:
- 5
- FQGSHIPYT.
22 more elements
A method for the treatment of residual congestion in a patient with heart failure who has been treated with diuretics, wherein residual congestion is defined as the presence of congestion after the treatment with diuretics, the method comprising:
- administering to a patient in the need thereof an effective amount of a humanized monoclonal antibody or fragment thereof which comprises a heavy and light chain, wherein the heavy chain comprises the sequences:
- SEQ ID NO:
- 1
- GYTFSRYW,
- SEQ ID NO:
- 2
- ILPGSGST,
- and
- SEQ ID NO:
- 3
- TEGYEYDGFDY
- and a light chain that comprises the sequences:
- SEQ ID NO:
- 4
- QSIVYSNGNTY,
- SEQUENCE:
- RVS,
- and
- SEQ ID NO:
- 5
- FQGSHIPYT;
- and
- wherein the humanized monoclonal antibody or fragment thereof comprises a sequence selected from the group consisting of:
- (AM-VH-C)
- SEQ ID NO:
- 6
- QVQLQQSGAELMKPGASVKISCKATGYTFSRYWIEWVKQRPGHGLEWIGEI
- LPGSGSTNYNEKFKGKATITADTSSNTAYMQLSSLTSEDSAVYYCTEGYEY
- DGFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE
- PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN
- HKPSNTKVDKRVEP KHHHHHH,
- (AM-VH1)
- SEQ ID NO:
- 7
- QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWISWVRQAPGQGLEWMGRI
- LPGSGSTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCTEGYEY
- DGFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE
- PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN
- HKPSNTKVDKRV EPKHHHHHH,
- (AM-VH2-E40)
- SEQ ID NO:
- 8
- QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWIEWVRQAPGQGLEWMGRI
- LPGSGSTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCTEGYEY
- DGFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE
- PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN
- HKPSNTKVDKRV EPKHHHHHH,
- (AM-VH3-T26-E55)
- SEQ ID NO:
- 9
- QVQLVQSGAEVKKPGSSVKVSCKATGYTFSRYWISWVRQAPGQGLEWMGEI
- LPGSGSTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCTEGYEY
- DGFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE
- PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN
- HKPSNTKVDKRV EPKHHHHHH,
- (AM-VH4-T26-E40-E55)
- SEQ ID NO:
- 10
- QVQLVQSGAEVKKPGSSVKVSCKATGYTFSRYWIEWVRQAPGQGLEWMGEI
- LPGSGSTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCTEGYEY
- DGFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE
- PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN
- HKPSNTKVDKRV EPKHHHHHH,
- (AM-VL-C)
- SEQ ID NO:
- 11
- DVLLSQTPLSLPVSLGDQATISCRSSQSIVYSNGNTYLEWYLQKPGQSPKL
- LIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHIPYT
- FGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQW
- KVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
- GLSSPVTKSFNRGEC,
- (AM-VL1)
- SEQ ID NO:
- 12
- DVVMTQSPLSLPVTLGQPASISCRSSQSIVYSNGNTYLNWFQQRPGQSPRR
- LIYRVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPYT
- FGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQW
- KVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
- GLSSPVTKSFNRGEC,
- and
- (AM-VL2-E40)
- SEQ ID NO:
- 13
- DVVMTQSPLSLPVTLGQPASISCRSSQSIVYSNGNTYLEWFQQRPGQSPRR
- LIYRVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPYT
- FGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQW
- KVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ
- GLSSPVTKSFNRGEC.
85 more elements
Dependencies are inferred from the claim text.